title: [Current value of seminal vesicle biopsy in patients with prostate cancer and influence of radical prostatectomy in patients with seminal vesicle invasion].
abstract: OBJECTIVE
  To evaluate if radical prostatectomy may positively influence cancer-specific survival (CSS), hormone-resistance-free time, metastasis-free time, and quality of life(QoL) of patients with prostate adenocarcinoma and seminal vesicle invasion, and also to update our thoughts about seminal vesicle biopsy.
  
  
  METHODS
  114 patients were included. Forty-six cases were diagnosed of seminal vesicle invasion after radical prostatectomy; 68 cases were diagnosed of seminal vesicle invasion after biopsy, not undergoing then surgery. Cancer specific survival, time to hormone resistance from the start of hormonal treatment, metastasis free time and QoL, measured as need for hospital care, were compared between groups. Median follow-up time was 52.6 mos.
  
  
  RESULTS
  There were not statistically significant differences between groups in CSS, time to hormone resistance, metastasis free time and QoL. Three and five-year cancer specific survival were 100% and 80.77% for the radical prostatectomy group and 74.4% and 56.2% for the biopsy group. Primary grade and Gleason Score were independent predictors for CSS in the Cox regression test; clinical stage was independent predictor for time to hormone resistance.
  
  
  CONCLUSIONS
  Radical prostatectomy as monotherapy does not show a statistically significant influence on followup time, CSS, time to hormone resistance, metastasis free time or QoL in patients with prostate cancer and seminal vesicle invasion associated with other bad prognostic factors (unfavourable Gleason and PSA). The value of seminal vesicle biopsy remains for the study of new multimodal treatments, such as chemotherapy + surgery, and it is to be defined in the planning of radio and cryosurgery.
authors.affiliation: Servicio de Urología, Hospital Universitario Miguel Servet, Pso. Isabel la Católica, 1 y 3, 50009 Zaragoza, España. callepuz@salud.aragon.es
authors.forename: Carlos Alberto Allepuz
authors.initials: CA
authors.lastname: Losa
authors.forename: Angel Borque
authors.initials: AB
authors.lastname: Fernando
authors.forename: Vicente Andrés
authors.initials: VA
authors.lastname: Lázaro
authors.forename: Francesc Filipo
authors.initials: FF
authors.lastname: Berlanga
authors.forename: Patricia Serrano
authors.initials: PS
authors.lastname: Frago
authors.forename: Marta Allúe
authors.initials: MA
authors.lastname: López
authors.forename: María Jesús Gil
authors.initials: MJ
authors.lastname: Sanz
authors.forename: Pedro Gil
authors.initials: PG
authors.lastname: Martínez
authors.forename: Luis Angel Rioja
authors.initials: LA
authors.lastname: Sanz
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery*; D000368:Aged; D001706:Biopsy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery*; D012669:Seminal Vesicles / Q000473:pathology*